Soleus Capital Management L.P. Takes $1.64 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Soleus Capital Management L.P. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,300 shares of the biopharmaceutical company's stock, valued at approximately $1,638,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares in the last quarter. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $28,000. Avalon Trust Co acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. Finally, Private Wealth Management Group LLC grew its holdings in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 39 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have commented on REGN shares. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Bernstein Bank reduced their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Royal Bank of Canada reduced their target price on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Finally, Truist Financial reduced their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $890.60.

Regeneron Pharmaceuticals Trading Down 1.7%

Shares of REGN stock traded down $10.17 during mid-day trading on Wednesday, reaching $604.62. 1,089,118 shares of the stock traded hands, compared to its average volume of 795,612. The stock's fifty day simple moving average is $595.54 and its two-hundred day simple moving average is $679.20. Regeneron Pharmaceuticals, Inc. has a 1-year low of $520.50 and a 1-year high of $1,211.20. The company has a market cap of $65.28 billion, a price-to-earnings ratio of 15.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the business posted $9.55 earnings per share. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.